Who are Gain Therapeutics's investors?

Gain Therapeutics's investors include 3B Future Health Fund, TiVenture SA.

Gain Therapeutics

NASDAQ: GANX

2 known investors

Gain Therapeutics develops small molecule drugs for neurodegenerative diseases using an AI-powered drug discovery platform that identifies novel binding sites on disease-related proteins. The company's lead candidate, rexaceract, targets GBA-Parkinson's disease and is in Phase I clinical trials.

AI & Machine Learning Biotech Medical Devices

Investors · 2

3B Future Health FundMonaco · $12M

TiVenture SALugano

Competitors · 1

by search overlap

Oup73 shared keywordsOxford University Press publishes research, educational, and reference materials, including reports on reading and children's learning, and reference resources such as its dictionary "Word of the Day." It serves readers, educators, and learners across a wide range of subjects worldwide.

Companies competing with Gain Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Gain Therapeutics do?: Gain Therapeutics develops small molecule drugs for neurodegenerative diseases using an AI-powered drug discovery platform that identifies novel binding sites on disease-related proteins. The company's lead candidate, rexaceract, targets GBA-Parkinson's disease and is in Phase I clinical trials.
Who are Gain Therapeutics's investors?: Gain Therapeutics's investors include 3B Future Health Fund, TiVenture SA.